LabBook September 26, 2014

Haskell Hall, on the University of Chicago campus (Photo: Matt Wood)

Haskell Hall, on the University of Chicago campus (Photo: Matt Wood)

This week’s rundown of recent research publications of note from University of Chicago scientists and physicians:

Second malignancies in patients with neuroblastoma: The effects of risk-based therapy: Mark Applebaum, Tara Henderson, Sang Mee Lee, Navin Pinto, Samuel Volchenboum and Susan Cohn — Pediatric Blood & Cancer

From the abstract: “To investigate the incidence of second malignant neoplasms (SMN) for patients with neuroblastoma, we analyzed patients from the SEER database according to three treatment eras (Era 1: 1973–1989, Era 2: 1990–1996, and Era 3: 1997–2006) corresponding to the introduction of multi-agent chemotherapy, risk-based treatment, and stem cell transplant … This study showed no increase in the incidence of SMNs for children treated in the most recent treatment era as compared to earlier Eras. However, as the risk for developing SMN does not plateau, the number of SMNs will likely continue to rise in the cohort of patients treated after 1996.”

US News and World Report Cancer Hospital Rankings: Do They Reflect Measures of Research Productivity? Including Jeffrey Goldstein — PLoS One

From the abstract: “Prior research has faulted the US News and World Report hospital specialty rankings for excessive reliance on reputation, a subjective measure of a hospital’s performance … To determine whether and to what extent reputation correlates with objective measures of research productivity among cancer hospitals … We ascertained the number of NCI funded grants, and the cumulative funds received by each cancer center. Additionally, we identified the number of phase I, phase II, and phase III studies published and indexed in MEDLINE, and registered at … Contrary to prior criticism, the majority of reputation, used in US News and World Rankings, can be explained by objective measures of research productivity among cancer hospitals.”

Sulfonylurea Treatment Before Genetic Testing in Neonatal Diabetes: Pros and Cons: Including David Carmody, Charles Bell, Jessica Hwang, Jazzmyne Dickens, Rochelle Naylor, Louis Philipson and Siri Atma Greeley — The Journal of Clinical Endocrinology & Metabolism

From the abstract: “Diabetes in neonates nearly always has a monogenic etiology. Earlier sulfonylurea therapy can improve glycemic control and potentially neurodevelopmental outcomes in children with KCNJ11 or ABCC8 mutations, the most common gene causes … Sulfonylurea therapy appears to be safe and often successful in neonatal diabetes patients before genetic testing results are available; however, larger numbers of cases must be studied. Given the potential beneficial effect on neurodevelopmental outcome, glycemic control and the current barriers to expeditious acquisition of genetic testing, an empiric inpatient trial of sulfonylurea can be considered. However, obtaining a genetic diagnosis remains imperative to inform long-term management and prognosis.”

About Matt Wood (531 Articles)
Matt Wood is a senior science writer and manager of communications at the University of Chicago Medicine & Biological Sciences Division.
%d bloggers like this: